Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)
It plans to deliver over 300 million doses to the Indian government
The company will market it under the brand name Molflu
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
The hospital has recently launched Radionuclide therapy
Patient with acute Covid-19 infection treated at BGS Gleneagles Global Hospital
Trastuzumab is monoclonal antibody used to treat human epidermal growth factor receptor 2 positive (HER2+) breast cancer and metastatic gastric cancers
The VaxIT app, developed on the Salesforce platform for Azim Premji Foundation and its partners, captures the status of vaccinations to help individuals plan and stay updated on their progress
Prucalopride medicine in the form of Orally Disintegrating Strips are most convenient dosage form for geriatric patients
2022 is going to be the year of opportunities and innovations from the medical industry in India
Subscribe To Our Newsletter & Stay Updated
